Why to invest in Medicortex Finland Oy?
TBI is the leading cause of central nervous system impairment and there is no reliable way to detect mild injuries
Medicortex is introducing, in Finland, a new diagnostic method for a huge need – detection of brain injury and concussion.
Our test – detecting a biomarker in a non-invasive sample (urine or saliva) – will address a TBI point of care (POC) diagnostics market that estimated to exceed €2 billion annually
Large customer potential and variable clients.
Current company valuation is ca. 6.6 M€.
Investor has an exit opportunity if the company is listing on First North at Nasdaq Helsinki (to be considered by the BOD when the valuation is above 10 M€).
A team of four people keeps the costs low and the organization lean.
Using professional sub-contractors with qualified track record
Investments will be used for the clinical trial and product development.
Basic development including preclinical trial and proof-of-concept human testing has been done.
Patent applications and PCT have been filed.
Exciting Company, won twice an innovation prize.
The company is currently running a larger clinical trial to (up to 160 patients) to validate the clinical relevance of the biomarkers. The first part (60 patients) is near its end. The study is being carried out in three Finnish hospitals; Tyks, Satakunta Central Hospital, Vaasa Central Hospital.